Abstract
Good clinical practice requires a close, cooperative, and multidisciplinary treatment network for patients and relatives. The effects of schizophrenia on a patient’s life can create such difficulties and impairments that multidisciplinary care providers have to work together closely.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
The 2009 National Institute for Health and Clinical Excellence guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). The National Institute for Health and Clinical Excellence website. www.nice.org.uk/guidance/CG82/NICEGuidance. Accessed April 2, 2012.
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd compendium. Arlington, VA: APA, 2004.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94-103.
Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13 suppl 1):7S-57S.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39:1-30.
Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry. 2007;68(suppl 7):1-48.
Lambert M. Taschenatlas der Pharmakotherapie psychotischer Störungen. Stuttgart, Germany: Thieme-Verlag, 2009.
Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123:411-422.
Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55(suppl B):133-136.
The International Psychopharmacology Algorithm Project schizophrenia algorithm. The International Psychopharmacology Algorithm Project website. www.ipap.org/pdf/schiz/ IPAP_Schiz_flowchart20060327.pdf. Accessed April 2, 2012.
Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother. 2008;12:2027-2038.
Lambert M, Naber D, Huber CG. Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother. 2008;9:2039-2051.
Bruch SM, Zeller S. Agitation I: overview of agitation and violence. In: Glick RL, Berlin JS, Fishkind AB, Zeller SL, eds. Emergency Psychiatry: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:117-124.
Allen MH, Currier GW, Carpenter D, et al. Treatment of behavioral emergencies. J Psychiatr Pract. 2005;11:5-108.
Lambert M, Naber D, eds. Current Schizophrenia. 2nd edn. New York, NY: Springer Healthcare; 2009.
Stroup TS, Marder SR, Lieberman JA. Pharmacotherapies. In: Lieberman JA, Stroup TS, Perkins DO, eds. Essential Schizophrenia. Arlington, VA: American Psychiatric Publishing, Inc.; 2012:173-206.
Haldol [package insert]. Titusville, NJ: Ortho-McNeil Neurologics; 2011.
Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
Geodon [package insert].New York, NY: Roerig; 2010.
Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone.CNS Spectr. 2005;10(suppl 17):1-20.
Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry. 1999;33:660-666.
Cookson J, Taylor D, Katona C. Violence: assessing risk and acute tranquilisation. In: Use of Drugs in Psychiatry. 5th edn. London, England: The Royal College of Psychiatrists; 2002:154-162.
Addington D, Bouchard R-H, Goldberg J, et al. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(suppl 1):1S-56S.
Droperidol injection [package insert]. Shirley, NY: American Regent, Inc.; 2009.
Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
Kerwin RW, Bolonna A. Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat. 2005;11:101-106.
Remington G, Saha A, Chong S-A, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.
Nasrallah HA, Tandon R. Classic antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2009:533-554.
Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. BMJ. 1994;309:54.
Davis, JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psych. 1993;54(suppl):24-30.
Anderson CM, Reiss DJ, Hogarty GE. Schizophrenia and the Family: A Practitioner’s Guide to Psychoeducation and Management. New York, NY: The Guilford Press; 1986.
Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatr Scand. 1990;82(suppl 358):151-157.
Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23:3-9.
Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.
Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181:422-427.
Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.
Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-230.
Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25:1780-1790.
Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164:870-876.
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464-470.
Pelonero AL, Levenson JL, Pandurangi AK.. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163-1172.
De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15-22.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obes Res. 1998;6(suppl 2):51S-209S.
Zipursky RB, Gu H, Green AI, Perkins DO, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5:437-440.
Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491.
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Institutes of Health website. www.nhlbi.nih.gov/guidelines/cholesterol/ atp3xsum.pdf. Accesed April 2, 2012.
De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14-26.
McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22:46-55.
Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22:90-97.
Dursun SM, Wildgust HJ, Strickland P, Goodwin GM, Citrome L, Lean M. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol. 2008;22:3-5.
Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28 (suppl 1):69-82.
Hellewell, JSE. Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multi-national survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics. Poster presented at: 13th European College of Neuropsychopharmacology Congress; September 9-13, 2000; Munich, Germany.
Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010(12): CD000088.
Mari JJ, Streiner DL. An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychol Med. 1994;24:565-578.
Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry. 2006;163:365-373.
World Health Organization. Mental Health and Work: Impact, Issues and Good Practices. Geneva, Switzerland: World Health Organization; 2000.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Healthcare, a part of Springer Science+Business Media
About this chapter
Cite this chapter
Lambert, M., Naber, D. (2013). Organization of Care and Treatment. In: Lambert, M. (eds) Current Schizophrenia. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-68-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-908517-68-5_3
Published:
Publisher Name: Springer Healthcare, Heidelberg
Print ISBN: 978-1-908517-46-3
Online ISBN: 978-1-908517-68-5
eBook Packages: MedicineMedicine (R0)